Phaseline

Targets › LAMA3

LAMA3 (Laminin subunit alpha-3): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Other.

Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components.; FUNCTION: Laminin-5 is thought to be involved in (1) cell adhesion via integrin alpha-3/beta-1 in focal adhesion and integrin alpha-6/beta-4 in hemidesmosomes, (2) signal transduction via…. (UniProt, Q16787)

Open in Phaseline: the race on LAMA3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fundación DEBRA Chile, Niños Piel de CristalELK-003 (Standarized Amniotic Fluid Secretome Eye Drops)
Amniotic fluid secretome containing extracellular matrix proteins (collagen type VII, lami
COL7A1, LAMA3Phase 1Junctional Epidermolysis Bullosa–
University of Southern CaliforniaGentamicin
Bacterial 70S ribosome inhibitor
LAMB3, LAMA3, LAMC2Phase 1Junctional Epidermolysis Bullosa–

Conditions

Junctional Epidermolysis Bullosa (2)

Modalities

protein or peptide (1), small molecule (1)

Companies

Fundación DEBRA Chile, Niños Piel de Cristal (1) University of Southern California (1)

Related targets

COL7A1 (1) LAMB3 (1) LAMC2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.